Literature DB >> 18584575

The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials.

James L Snyder1, Thomas G Bowers.   

Abstract

Random controlled trials on the efficacy of naltrexone and acamprosate in the treatment of alcohol dependence were reviewed, using a Relative Benefit (RB) analysis approach. A total of 42 studies were included, showing acamprosate use demonstrated a modest improvement, with a RB of 1.76 at three month follow-up. Short-term administration of naltrexone significantly reduced the relapse rate, but was not associated with modification in the abstinence rate. There was insufficient data available to ascertain the efficacy of naltrexone and acamprosate over prolonged periods of time, or the effectiveness of the medications relative to each other.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18584575     DOI: 10.1080/00952990802082198

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  13 in total

1.  Systematic Review of Combined Pharmacotherapy for the Treatment of Alcohol Use Disorder in Patients Without Comorbid Conditions.

Authors:  Andrew C Naglich; Austin Lin; Sidarth Wakhlu; Bryon H Adinoff
Journal:  CNS Drugs       Date:  2018-01       Impact factor: 5.749

2.  Comparison of healthcare utilization among patients treated with alcoholism medications.

Authors:  Tami L Mark; Leslie B Montejano; Henry R Kranzler; Mady Chalk; David R Gastfriend
Journal:  Am J Manag Care       Date:  2010       Impact factor: 2.229

3.  Glyoxalase 1 (GLO1) Inhibition or Genetic Overexpression Does Not Alter Ethanol's Locomotor Effects: Implications for GLO1 as a Therapeutic Target in Alcohol Use Disorders.

Authors:  Amanda M Barkley-Levenson; Frances A Lagarda; Abraham A Palmer
Journal:  Alcohol Clin Exp Res       Date:  2018-04-18       Impact factor: 3.455

Review 4.  Glutamatergic medications for the treatment of drug and behavioral addictions.

Authors:  M Foster Olive; Richard M Cleva; Peter W Kalivas; Robert J Malcolm
Journal:  Pharmacol Biochem Behav       Date:  2011-04-22       Impact factor: 3.533

Review 5.  Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.

Authors:  Elizabeth M Oliva; Natalya C Maisel; Adam J Gordon; Alex H S Harris
Journal:  Curr Psychiatry Rep       Date:  2011-10       Impact factor: 5.285

6.  Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.

Authors:  Doug Hyun Han; Sun Mi Kim; Jung Eun Choi; Kyung Joon Min; Perry F Renshaw
Journal:  J Psychopharmacol       Date:  2013-01-16       Impact factor: 4.153

Review 7.  A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials.

Authors:  Stacia M DeSantis; Huirong Zhu
Journal:  Med Decis Making       Date:  2014-06-16       Impact factor: 2.583

Review 8.  Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?

Authors:  Natalya C Maisel; Janet C Blodgett; Paula L Wilbourne; Keith Humphreys; John W Finney
Journal:  Addiction       Date:  2012-10-17       Impact factor: 6.526

Review 9.  How confident should we be that smoking cessation treatments work?

Authors:  John R Hughes
Journal:  Addiction       Date:  2009-08-04       Impact factor: 6.526

10.  Long-lasting alterations in membrane properties, k(+) currents, and glutamatergic synaptic currents of nucleus accumbens medium spiny neurons in a rat model of alcohol dependence.

Authors:  Vincent N Marty; Igor Spigelman
Journal:  Front Neurosci       Date:  2012-06-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.